Does Rallies show Form 4 insider transactions for VRCA?

Yes. Rallies tracks VRCA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VRCA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VRCA. It does not provide personalized investment advice.

VRCA (Verrica Pharmaceuticals Inc. Common Stock) Stock Analysis - Insider Trades

Verrica Pharmaceuticals Inc. Common Stock (VRCA) is a publicly traded Healthcare sector company. As of May 21, 2026, VRCA trades at $6.14 with a market cap of $100.84M and a P/E ratio of -5.37. VRCA moved +6.80% today. Year to date, VRCA is -32.13%; over the trailing twelve months it is -6.39%. Its 52-week range spans $3.28 to $17.49. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces VRCA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VRCA stock inside the company?

Recent VRCA insider activity includes Rosenberg Noah L. bought 2.36K, Kirby John J. bought 3.54K, Zawitz David bought 10.00K, Rieger Jayson bought 94.31K, and Manning Paul B bought 1.38M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VRCA Key Metrics

Key financial metrics for VRCA
Metric	Value
Price	$6.14
Market Cap	$100.84M
P/E Ratio	-5.37
EPS	$-1.11
Dividend Yield	0.00%
52-Week High	$17.49
52-Week Low	$3.28
Volume	0
Avg Volume	0
Revenue (TTM)	$37.16M
Net Income	$-17.83M
Gross Margin	0.00%

Recent VRCA Insider Trades

Rosenberg Noah L. bought 2.36K (~$10.00K) on Nov 25, 2025.
Kirby John J. bought 3.54K (~$15.00K) on Nov 25, 2025.
Zawitz David bought 10.00K (~$42.42K) on Nov 25, 2025.
Rieger Jayson bought 94.31K (~$400.11K) on Nov 25, 2025.
Manning Paul B bought 1.38M (~$5.84M) on Nov 25, 2025.

Latest VRCA News

Verrica Q1 Revenue Jumps 60% to $6.7M, Net Loss Narrows — May 13, 2026
Verrica Posts $5M Q1 Revenue; YCANTH Units Rise 51.3% YoY and Launch in Japan — May 12, 2026
Verrica CEO to Present April 15 at Needham Conference, Spotlighting YCANTH® and VP-315 — Apr 6, 2026
Verrica Q4 Net Loss Narrows to $8.1M as YCANTH Rx Rollout Expands — Mar 11, 2026
Verrica Posts $35.6M 2025 Revenue, Grows YCANTH Sales 130% and Launches Phase 3 Trials — Mar 11, 2026

VRCA Analyst Consensus

2 analysts cover VRCA: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.

Common questions about VRCA

Who is trading VRCA stock inside the company?: Recent VRCA insider activity includes Rosenberg Noah L. bought 2.36K, Kirby John J. bought 3.54K, Zawitz David bought 10.00K, Rieger Jayson bought 94.31K, and Manning Paul B bought 1.38M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VRCA?: Yes. Rallies tracks VRCA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VRCA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VRCA. It does not provide personalized investment advice.